次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。順調なR&DやPL等の進捗・拡大の加速。笑。
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
下期、R&D等の拡充・進捗は着実に進み、年度期末に向けての次なる展開・進捗が楽しみですね。笑。
成長相場の動向：上抜け圏にて強気相場後の時間軸調整は良好。控える材料と共に強気相場待ち。笑。
・The share is getting closer to its long-term support in weekly data, at JPY 10900, which offers good timing for buyers.
・Graphically speaking, the timing seems perfect for purchasing the stock close to the JPY 12490 support.
・The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
時間軸調整後の次なる展開も楽しみです。笑。
※The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%. (1/23)
次なる飛躍へ。順調な進捗と共に更なる成長の黎明期にて育ちゆく相場。控える材料と共に水準訂正。笑。
予定されていた業績の急成長と共に更なる成長戦略が始動。順調なR&DやPL等の進捗・拡大の加速。笑。
The scope of the opportunity using the Heptares approach extends well beyond our growing Pipeline.
下期、R&D等の拡充・進捗は着実に進み、年度期末に向けての次なる展開・進捗が楽しみですね。笑。
成長相場の動向：上抜け圏にて強気相場後の時間軸調整は良好。控える材料と共に強気相場待ち。笑。
・The share is getting closer to its long-term support in weekly data, at JPY 10900, which offers good timing for buyers.
・Graphically speaking, the timing seems perfect for purchasing the stock close to the JPY 12490 support.
・The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
時間軸調整後の次なる展開も楽しみです。笑。
※The COPD Asia-Pacific market will be valued at $7.3 billion in 2022, growing from $3.7 billion in 2015 at a CAGR of 10.2%. (1/23)